D printing is a good option for bioreactor production. The flexibility of the approach outweighs concerns about higher costs.
On December 1, Pfizer became the first big pharma to commit to take to market a late-stage biologic drug produced in plant cells. It acquired rights to taligurase alfa, a form of the enzyme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results